Recombinant holotoxoid vaccine against botulism

Area of Science:

• Microbiology
• Immunology
• Toxicology

Background:

• Botulinum neurotoxins (BoNT) are highly toxic proteins classified as Category A Select Agents.
• The existing botulism vaccine has limited availability, necessitating the development of novel vaccine strategies.
• Botulism poses a significant public health threat due to the extreme toxicity of BoNT.

Purpose of the Study:

• To develop and evaluate a novel recombinant botulinum neurotoxin type A (BoNT/A) toxoid as a potential vaccine candidate.
• To assess the safety and immunogenicity of the engineered BoNT/A toxoid, termed BoNT/A(RYM).
• To determine the protective efficacy of BoNT/A(RYM) against botulinum neurotoxin challenge in a mouse model.

Main Methods:

• Production of a recombinant BoNT/A toxoid (BoNT/A(RYM)) with specific amino acid substitutions (R363A Y365F).
• Assessment of BoNT/A(RYM) catalytic activity and toxicity in vitro and in vivo (mice).
• Immunization of mice with BoNT/A(RYM) followed by challenge with botulinum neurotoxin; analysis of immune response and neutralizing antibody activity.

Main Results:

• BoNT/A(RYM) was confirmed to be non-catalytic for SNAP25 and non-toxic to mice.
• Immunization with BoNT/A(RYM) provided protection in mice comparable to a chemically inactivated BoNT/A toxoid.
• The toxoid elicited immune responses targeting both light and heavy chains of BoNT/A, and neutralizing antibodies blocked toxin activity in neuronal cells and ganglioside binding.

Conclusions:

• BoNT/A(RYM) represents a safe and effective holotoxoid vaccine candidate against botulism.
• The engineered toxoid successfully elicits neutralizing antibodies capable of blocking botulinum neurotoxin's mechanism of action.
• This novel vaccine strategy addresses the limitations of current botulism countermeasures.